What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply

Related Experiment Video

Updated: Jan 4, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K

Jeremie Calais1, Francesco Ceci2, Matthias Eiber3

  • 1Ahmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, University of California Los Angeles, CA 900095-7370, USA; Institute of Urologic Oncology, University of California Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, CA, USA.

The Lancet. Oncology
|November 2, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

608
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K